CRISPR Therapeutics, a biotech firm specializing in gene-based medicines headquartered in Switzerland with a manufacturing plant in Framingham, announced Thursday updated trial results for its cell therapy.
CRISPR Therapeautic’s CTX110, is a wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies, per the release.
Currently, the drug is in a phase one trial to test the medicine’s safety and efficacy.
The clinical trial evaluates adult patients with relapsed or refractory B-cell CD19+ malignancies who have received at least two prior lines of therapy, according to CRISPR.
Thirty patients with large B-cell lymphoma (LBCL) enrolled for the trial, of which 26 patients received CTX110. The results yielded a 58% overall response rate and 38% complete response rate with a single dose of CTX110, per the announcement.
“We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available ‘off-the-shelf’ therapy with efficacy similar to autologous CAR-T and a differentiated safety profile,” said Samarth Kulkarni, CEO of CRISPR Therapeutics, in a press release.
